Tag : Inhibitor

Pharma / Biotech

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Newsemia
Related Articles Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. Ann Oncol. 2020...
Cardiology

Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury.

Newsemia
Related Articles Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 2020 Mar 18;: Authors: Li...
Pharma / Biotech

Safety, Pharmacokinetics and Pharmacodynamics of Branebrutinib (BMS-986195), a Covalent, Irreversible Inhibitor of Bruton's Tyrosine Kinase: Randomised Phase I, Placebo-Controlled Trial in Healthy Participants.

Newsemia
Safety, Pharmacokinetics and Pharmacodynamics of Branebrutinib (BMS-986195), a Covalent, Irreversible Inhibitor of Bruton’s Tyrosine Kinase: Randomised Phase I, Placebo-Controlled Trial in Healthy Participants. Br J...
Gastroenterology

BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling

Newsemia
BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling Source link...
AI/ML

Three Major Phosphoacceptor Sites in HIV-1 Capsid Protein Enhances its Structural Stability and Resistance against Inhibitor: Explication through Molecular Dynamics Simulation, Molecular Docking and DFT Analysis.

Newsemia
Related Articles Three Major Phosphoacceptor Sites in HIV-1 Capsid Protein Enhances its Structural Stability and Resistance against Inhibitor: Explication through Molecular Dynamics Simulation, Molecular Docking...
Gastroenterology

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

Newsemia
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b,...
Gastroenterology

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Newsemia
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer Source link...
Latest News

New risk prediction models in England may lead to targeted PCSK9 inhibitor treatment, for patients with established cardiovascular disease

Newsemia
Tillmann, T; (2020) New risk prediction models in England may lead to targeted PCSK9 inhibitor treatment, for patients with established cardiovascular disease. European Journal of...
Pharma / Biotech

LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: application to a pharmacokinetic study.

Newsemia
Related Articles LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: application to a pharmacokinetic study. Biomed Chromatogr. 2020 Feb 28;:e4816 Authors:...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy